|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer-Related Problem/Condition | |||||
| 2 | Interventions listed in this trial | ||||
| enalapril maleate | |||||
| quality-of-life assessment | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Enalapril | |||||
| Enalaprilat | |||||
| 4 | More general drug interventions related to this trial | ||||
| Angiotensin-Converting Enzyme Inhibitors | |||||
| Antihypertensive Agents | |||||
| Cardiovascular Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Protease Inhibitors | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| Pediatric Oncology Group | |||||
| National Cancer Institute (NCI) | |||||